Company intelligence / Profile preview
United Immunity Co., Ltd.
Chuo-ku, Tokyo, Japanunitedimmunity.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Developing nanotechnology-based drug delivery systems that target myeloid cells to reprogram tumor-associated macrophages and activate T cells. Lead candidate UI-102 is advancing from preclinical to Phase 1 for treatment of immune-resistant cold solid tumors.
- Therapeutic areas
- PulmonologyMetabolic DisordersImmunologyOncologyInfectious Diseases
- Modalities
- Nanogelslipid nanoparticlesmRNAsiRNADNAsmall moleculespeptidesproteins
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Xyphos Biosciences (Astellas subsidiary)AstraZeneca
Beyond the preview
Go deeper on United Immunity Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on United Immunity Co., Ltd..